We’ve been discussing this paper for weeks.
Now the phase 3 trial in @natureportfolio.nature.com
carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩
🔎 Social media amplification requires critical judgment
Also worth considering: are we even measuring the right mechanism?
Some mAbs may derive clinical activity from Fc-mediated effects (as seen with CTLA-4), not just target blockade.
Nice perspective here: ascopubs.org/doi/10.1200/...
New here on Bluesky 🚀
Medical oncologist focused on clinical research, IO and translational science
#Oncology #TranslationalResearch #Cancer
Honoured to join @JNCI_NOW as Social Media Editor 🚀
Excited to contribute to the digital voice of JNCI Journals and help amplify clinically relevant research with global impact.
Scientific publishing is evolving and context & community matter more than ever
#Oncology #SciComm
Does TIGIT benefit no one…
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
